Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis

Nippon Boehringer Ingelheim Co., Ltd.0 个研究点目标入组 15 人开始时间: 待定最近更新: 2024年8月9日

试验速览

暂无简介。

•male or female who is >= 18 (or who is of legal age in countries where that is greater than 18) and =< 75 years old at screening (Visit 1a)
•clinical signs of CSPH as described by either one of the points below:
•documented endoscopic proof of oesophageal varices and / or gastric varices at screening (Visit 1b) or within 3 months prior to screening (Visit 1b)
•documented endoscopic-treated oesophageal varices as preventative treatment
•CSPH defined as baseline HVPG >= 10 mmHg (measured at Visit 1c), based on a local interpretation of the pressure tracing
•diagnosis of compensated alcohol-related cirrhosis. Diagnosis must be based on histology (historical data is acceptable) or on clinical evidence of cirrhosis (e.g. platelet count < 150 x 109/L [150 x 103/microL], nodular liver surface on imaging or splenomegaly)
•abstinence from alcohol for a minimum of 6 months prior to screening (Visit 1a), which, based on Investigator judgement, can be maintained throughout the trial
•willing and able to undergo HVPG measurements per protocol (based on Investigator judgement)
•if receiving statins, NSBBs or carvedilol must be on a stable dose for at least 3 months prior to screening (Visit 1b), with no planned dose change throughout the trial

•previous clinically significant decompensation events (e.g. ascites [more than perihepatic ascites], VH and / or apparent HE)
•history of other forms of chronic liver disease(e.g. non-alcoholic steatohepatitis [NASH], Hepatitis B virus [HBV], untreated HCV, autoimmune liver disease, primary biliary sclerosis, primary sclerosing cholangitis, Wilsons disease, haemachromatosis, alpha-
•1 antitrypsin [A1At] deficiency)
•alcohol-related liver disease (ARLD) without adequate treatment (e.g. lifestyle modification) or with ongoing pathological drinking behaviour
•SBP < 100 mmHg and DBP < 70 mmHg at screening (Visit 1a)
•Model of End-stage Liver Disease (MELD) score of >15 at screening (Visit 1a)
•hepatic impairment defined as a Child-Turcotte-Pugh score >= B8 at screening (Visit 1a)
•ALT or AST > 5 times upper limit of normal (ULN) at screening (Visit 1a)
•eGFR (CKD-EPI formula) < 20 mL/min/1.73 m2 at screening (Visit 1a)
•alpha-fetoprotein > 50 ng/mL (> 50 microg/L) at screening (Visit 1a)
•history of clinically relevant orthostatic hypotension, fainting spells or blackouts due to hypotension

Percentage change in HVPG from baseline (measured in mmHg) after 24 weeks of treatment

未报告次要终点

发起方